ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial
Status:
Terminated
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the event-free survival defined as the time from
randomisation to progression, death without progression, loss to follow up, whichever
occurred first..